A comparison of acute phase proteins and traditional risk factors as markers of combined plaque and intima-media thickness and plaque density in carotid and femoral arteries  by Muscari, A. et al.
A Comparison of Acute Phase Proteins and Traditional Risk Factors as
Markers of Combined Plaque and Intima-Media Thickness and
Plaque Density in Carotid and Femoral Arteries
A. Muscari1, C. Martignani1, L. Bastagli1, G. Poggiopollini1, V. Tomassetti1, L. Baldini1,
O. Cappelletti2, P. Boni2, G. Ravaglia1 and P. Puddu1
1Department of Internal Medicine, Cardioangiology, Hepatology, University of Bologna, Italy and
2Central Laboratory of the S.Orsola-Malpighi Hospital, Bologna, Italy
Objectives: to test the hypothesis that some acute phase proteins may be better independent predictors of objective measures
of arterial wall impairment than traditional risk factors.
Design: cross-sectional study.
Materials and Methods: C-reactive protein (CRP), fibrinogen, C3 complement and traditional risk factors were measured
in 288 men aged 55±64 years, randomly chosen from the local registry lists. By ultrasound assessment of the bifurcations of
carotid and femoral arteries, maximum combined plaque/intima-media thickness (CPIMTmax) and mean plaque density
(MPD, in a grey scale from 0 to 255) were also measured.
Results: in multivariate analysis only traditional risk factors remained associated with the overall CPIMTmax: smoking
(r 0.35, p5 0.0001), cholesterol (r 0.23, p 0.0001), age (r 0.22, p 0.0002), glucose (r 0.18, p 0.002) and
systolic blood pressure (r 0.13, p 0.02). However, with regard to carotid disease only, fibrinogen was the strongest
covariate of CPIMT (r 0.18, p 0.002). The overall MPD was independently associated with CRP (r 0.25,
p 0.0008), physical activity (r 0.19, p 0.009), triglycerides (r ÿ 0.18, p 0.02) and body mass index (r 0.15,
p 0.04). CRP was mainly associated with femoral MPD, while triglycerides were the major (inverse) covariate of
carotid MPD.
Conclusions: traditional risk factors are the main determinants of CPIMTmax, although fibrinogen seems to play a role in
carotids. CRP was associated with high density femoral plaques. Finally, no acute phase protein was independently
associated with low density, potentially vulnerable, plaques.
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Introduction
For reasons, as yet unknown, acute phase proteins
may be better predictors of future ischaemic events
than traditional vascular risk factors.1±5 The links
between acute phase proteins and such risk factors
are complex and incompletely defined.6±10 For
example, tumour necrosis factor a released from the
adipose tissue,11 or from sites of chronic inflamma-
tions, may bind to insulin receptors,12 cause insulin
resistance and originate the metabolic syndrome.13
Furthermore it is clear that atherosclerotic plaques,
especially those that are at highest risk of rupture,
are sites of intense inflammation.14,15 In a random
sample of 288 middle-aged men we have recently
reported16 differences between C-reactive protein
(CRP), fibrinogen and C3 complement in terms of
their relationship with traditional risk factors such as
age, cigarette smoking, alcohol consumption, choles-
terol, blood glucose, systolic blood pressure, and body
mass index (BMI). As an objective assessment of the
degree of atherosclerosis, in the same sample we have
also employed ultrasound to measure combined pla-
que/intima-media thickness (CPIMT) and mean
plaque density (MPD), at the carotid and femoral
bifurcations.17,18 The purpose of the present study is
to determine whether there is a stronger relationship
between CPIMT and MPD and acute phase proteins
than there is with traditional risk factors.
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Methods
Subjects
The study population consisted of 288 unselected men
aged 55±64 years as has been previously reported.10,16
Briefly, these subjects were randomly chosen from
those who agreed to participate (1111 out of 1846
invited, 60.4%) in the San Vitale Study epidemio-
logical survey in Bologna (Northern Italy). Lifestyle
information was obtained by a self-administered
questionnaire. Smoking was quantified as daily num-
ber of smoked cigarettes, while alcohol consumption
was expressed as number of drinks per week (where a
pint of beer, a glass of wine or a small glass of spirit
were considered a drink). All subjects underwent
blood pressure and body weight measurement, as
well as venous blood sampling and ultrasound assess-
ment of the carotid and femoral arteries. The popula-
tion included 42% hypertensives, 12% diabetics, 69%
hypercholesterolemics (total cholesterol4200 mg/dl),
34% current smokers, 30% ex-smokers, 12% with a
family history of myocardial infarction (at least one
first degree relative affected before 60 years of age)
and 40% physically active subjects (at least 90 minutes
a week of heavy work or sport). Moreover, 4% had
had a previous myocardial infarction, 4% were
affected by angina pectoris, 3% by peripheral arterial
disease and 14% by a recent (5one month) acute
inflammatory disease. Finally, 10% were taking
b-blockers, 15% ACE-inhibitors, 8% antiplatelet
drugs, 6% lipid lowering drugs, and 5% oral antidia-
betic drugs. None of the above prevalence data
differed significantly from the corresponding values
obtained in the original cohort of participants.10 Since
the sample included 54 subjects who were taking lipid
lowering drugs and/or who had recently suffered an
inflammatory episode, the analysis was repeated after
their removal, with substantially similar results to
those reported further. The study was approved by
the local Ethics Committee and all subjects provided
written informed consent.
Ultrasound measurements were performed by a
single operator (CM) with a Hewlett Packard Sonos
2500 duplex scanner using a high-resolution 7.5 MHz
linear transducer. In each subject the carotid and
femoral bifurcations were examined along a 3 cm
portion straddling the flow divider. At each of the
four sites, the maximum intima-media thickness
(CPIMTmax)17 or, in the presence of one or more
plaques, the maximum plaque thickness, was
recorded. Then, the maximum carotid value, the max-
imum femoral value and the maximum value in
the four sites were used in the subsequent assessments.
Preliminary analyses (data not shown) and other
studies17 had suggested that maximum, rather than
mean, values provide optimal correlations with risk
factors. Moreover, this combined parameter is more
influenced by the presence of plaques than by intima-
media thickness,19 and plaque thickness correlates
with a greater number of risk factors, and with higher
correlation coefficients, than intima-media thickness.19
On the other hand, with respect to plaque thickness
alone, the combined parameter offers the advantage of
being measurable in all subjects, even those without
plaques. Intima-media thickness was measured on the
basis of a longitudinal view of the artery, in the `` far''
wall with respect to the transducer. When a plaque
(defined as a localized region of increased intimal thick-
ness and density) was found, the probe was rotated
by 90, so that a transversal view was obtained: the
maximum plaque thickness was sought, and the den-
sitometric analysis was performed, within this view.
Densitometric analysis was performed following
the methods of El-Barghouty et al.,20 Beletski et al.18
and Grùnholdt et al.21 The main ultrasound para-
meters (dynamic range, depth range, power output
and frame rate) were kept constant, while gain control
was adjusted so that optimal B-mode images could be
obtained. All investigations were recorded on a S-VHS
videotape. In the presence of plaques the operator
outlined the whole cross section of the plaque, as
well as the lumen (black) area, using the software
incorporated in the ultrasonographer, and avoiding
the inclusion of possible areas with acoustic shadow-
ing. These images were printed out by a Sony Video
Graphic printer (UP-890MD) and then digitized by a
Hewlett Packard Scanjet 4P scanner interfaced with
the program Visioneer PaperPort, version 3.0.1, from
Visioneer Communications, Inc. The digitized images
were then processed by a second operator (L.Bal.)
with the program Photoshop, version 5.0, from
Adobe Systems, Inc. This program assigned a density
value to each pixel in the outlined region, in a grey
scale ranging from 0 to 255, and then generated the
frequency distribution of these densities. The median
of this distribution (median grey scale, MGS) was the
numeric parameter reassuming the density of the
region of interest. This parameter has been shown to
correlate directly with the fibrous and calcified com-
ponent of plaques and, inversely, with the intraplaque
content in lipid, haemorrhagic or thrombotic mater-
ial.18,21 Moreover, carotid plaque density, as assessed
by median grey scale, is inversely associated with the
occurrence of cerebral infarction.20,22,23 To obtain com-
parable values, blood density (i.e. the median density
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in the lumen area) was considered the background
density, and this value was subtracted from
the density in the plaque area.21 The so normalized
density value of each plaque was then used to obtain
the three main parameters for the following analyses:
the mean density in carotid plaques, the mean density
in femoral plaques, and the mean plaque density in all
the four sites explored.
Six to eight months after the first assessment, the
videotape recordings concerning 53 randomly chosen
plaques were re-examined by the same operator (CM).
Plaque thickness was measured and, similarly, plaque
images (plus the corresponding arterial lumen) were
outlined, printed and digitized for the second time.
The digitized images were then processed by another
operator (L.Bal.), as previously described, until nor-
malized density values were obtained. The mean of
the differences between the first and the second meas-
urement of plaque thickness was 0.03 mm (95% C.I.:
ÿ 0.01 to 0.06), with a repeatability coefficient24 of
0.26 mm. For plaque density, the mean difference, in
the MGS, was ÿ0.7 (95% C.I.: ÿ3.7 to 2.4), with a
repeatability coefficient of 22.0. Although correlation
analysis does not provide a reliable estimate of repeat-
ability,25 the correlation between the first and the
second series of values was good for both parameters
(r 0.98 for plaque thickness and r 0.94 for plaque
density).
The methods used to measure the biochemical vari-
ables in the 288 men of our population sample have
been described in detail elsewhere.10,16 In particular,
fibrinogen was measured with the method of Clauss,26
C3 complement with nephelometry (Behring kits,
Behringwerke AG, Marburg, Germany) and CRP with
a high-sensitivity nephelometric method (N Latex
CRP mono, Dade Behring, Liederbach, Germany).
The statistical analysis mainly consisted of multi-
variate analysis techniques. Univariate analysis (sim-
ple regressions and some unpaired t-tests) was
performed essentially as a preliminary step to multi-
variate analysis (multiple linear regressions): in each
initial multivariate model all the variables were
included, which, in univariate analysis, were asso-
ciated with CPIMTmax or MPD with p values 50.30.
Thereafter, multiple regression was repeated several
times, removing every time from the model the vari-
able with the highest p value, until all of the remaining
variables were significantly associated with their
dependent variable (backward elimination proced-
ure). All the variables that were not normally distrib-
uted were logarithmically transformed. Two tail tests
were performed and p values 50.05 were considered
significant.
Results
Figure 1 shows the frequency distributions of CPIMT-
max in all the 288 subjects, and of MPD in the 183
subjects with plaques, considering all the four arterial
sites examined. The distribution of both variables had
a positive skewness, which was greater for MPD. The
median and interquartile range for CPIMTmax were
2.29 mm (1.47±3.00 mm). The same values for MPD
were 32 (16ÿ 50, MGS). There was a weak inverse
correlation between the two variables, in both carotids
(rÿ0.25; p 0.011; n 104) and femorals (rÿ0.17;
p 0.025; n 163).
Factors associated with CPIMT
Table 1 shows the univariate associations (simple lin-
ear regressions) of the natural logarithm of CPIMT-
max with traditional risk factors and the three acute
phase proteins, in all the 288 men of our sample. The
assessments in carotids alone, in femorals alone, or in
all the four arteries together, are separately reported.
Fig. 1. Frequency distribution of maximum combined plaque/
intima-media thickness (CPIMTmax) in all the 288 subjects (upper
panel), and of mean plaque density in the 183 subjects with plaques
(lower panel), considering all the four arterial sites examined.
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The strongest correlation was the one with cigarette
smoking, in femoral arteries. Similarly, there was a
progressive and highly significant increase in the
medians of femoral CPIMTmax from never smokers
(1.5 mm), to ex-smokers (2.0 mm), up to current
smokers (2.5 mm, p5 0.0001 by variance analysis of
log-transformed data). The median of the overall
CPIMTmax was significantly greater in the subjects
with previous ischaemic events (especially myocardial
infarction, n 13, 3.1 mm) and in the subjects who
were taking antiplatelet drugs (n 24, 3.0 mm) or
oral antidiabetic drugs (n 15, 3.1 mm), than in the
subjects who did not present these characteristics
(2.2 mm, p5 0.001 for all comparisons).
To ascertain which associations were independent,
some multiple linear regressions were performed with
a backward elimination procedure, initially including
in the models all the variables associated with CPIMT-
max, in univariate analysis, with p values 5 0.30. The
final results are reported in Table 2. Considering the
four arteries together, the relationships with cigarette
smoking, cholesterol, age, blood glucose and systolic
blood pressure (in decreasing order of partial r) were
confirmed. Overall, these five traditional risk factors
explained 23% of CPIMTmax variance. Instead, the
correlations of CPIMTmax with the three acute phase
proteins and triglycerides were not confirmed.
In carotids alone the associations with age, smoking
and cholesterol were also confirmed, but in this site
the strongest association of CPIMTmax was with
fibrinogen. The univariate non significant association
with BMI, in multivariate analysis became borderline-
significant. However, these variables explained only
11% of CPIMTmax variability in carotids. The correla-
tions with systolic blood pressure and CRP were not
confirmed.
Finally, considering the femorals alone, cigarette
smoking, age, blood glucose and cholesterol remained
independently and strongly associated with CPIMT-
max (these four factors alone explained 27% of
CPIMTmax variance in femorals), while the univariate
associations with systolic blood pressure, triglycer-
ides, fibrinogen and CRP were not confirmed.
Factors associated with MPD
Overall, 408 arterial plaques (143 in the carotids and
265 in the femorals) were demonstrated in the 288
subjects studied. Table 3 reports the univariate corre-
lations of the natural logarithm of MPD with trad-
itional risk factors and acute phase proteins. MPD
was not associated with previous ischaemic events or
the use of any type of drug, although almost in all
Table 1. Univariate associations of CPIMTmax with risk factors and acute phase proteins in carotid and femoral arteries.
Any arteries Carotid arteries Femoral arteries
r coeff. p value r coeff. p value r coeff. p value
Age 0.19 0.001 0.17 0.004 0.21 0.0002
log smoking 0.30 50.0001 0.12 0.033 0.34 50.0001
log alcohol 0.01 0.856 ÿ0.04 0.514 ÿ0.03 0.640
BMI 0.06 0.303 0.10 0.084 0.04 0.473
Systolic blood pressure 0.19 0.001 0.15 0.008 0.14 0.014
Diastolic blood pressure 0.05 0.347 0.04 0.457 0.01 0.860
log insulin 0.00 0.955 0.01 0.892 0.01 0.800
log blood glucose 0.18 0.001 0.08 0.150 0.20 0.0005
Cholesterol 0.22 0.0001 0.12 0.043 0.21 0.0002
HDL cholesterol ÿ0.07 0.249 ÿ0.07 0.217 ÿ0.07 0.228
log triglycerides 0.21 0.0003 0.10 0.104 0.19 0.001
Fibrinogen 0.16 0.005 0.20 0.0004 0.14 0.020
log CRP 0.15 0.010 0.15 0.008 0.15 0.012
C3 complement 0.14 0.014 0.10 0.084 0.11 0.057
No. CPIMTmax (mm) p value CPIMTmax (mm) p value CPIMTmax (mm) p value
FHMI
No 254 2.20 (1.46±2.95) 0.173 1.30 (0.90±2.01) 0.194 2.00 (1.20±2.70) 0.167
Yes 34 2.35 (1.90±3.10) 1.40 (0.96±2.10) 2.18 (1.60±2.87)
Physical activity
No 172 2.30 (1.50±3.00) 0.198 1.33 (0.95±2.00) 0.286 2.10 (1.30±2.82) 0.236
Yes 116 2.18 (1.42±2.82) 1.20 (0.90±2.08) 2.00 (1.06±2.56)
All subjects (n 288) were considered in the assessment of each association. Values for CPIMTmax are median (interquartile range).
FHMI family history of myocardial infarction. HDLhigh density lipoprotein. p values of the variables included in the subsequent
multivariate analysis (p5 0.30) are marked in bold. For linear regressions the logarithm of CPIMTmax was used as dependent variable.
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these categories there was a non-significant tendency
towards higher density values (data not shown).
As for CPIMTmax, three multivariate analyses
were performed in order to identify the independent
associations of MPD in the three sites considered
(Table 4). In the subjects with plaques of any site,
CRP was the parameter most strongly associated
with MPD, together with physical activity, triglycer-
ides (inversely) and BMI. Considering the carotids
alone, the inverse association with triglycerides was
the strongest one, followed by the correlations with
age, BMI and physical activity, while the univariate
association with cholesterol was not confirmed.
Finally, the only variable independently associated
with MPD in the femoral arteries was CRP. The
proportion of MPD variability explained by these
variables was 11% in the four arteries, 15% in the
carotids and only 2% in the femorals.
Discussion
This study has compared acute phase proteins and
traditional vascular risk factors as markers of the
thickness and density of atherosclerotic lesions in a
random sample of middle-aged men. It should be
Table 2. Significant multivariate associations of CPIMTmax with risk factors and acute phase proteins in carotid and femoral arteries
(multiple linear regressions).
Any arteries Carotid arteries Femoral arteries
Partial r Seq. R2 p value Partial r Seq. R2 p value Partial r Seq. R2 p value
Age 0.22 0.03 0.0002 0.16 0.03 0.007 0.28 0.05 50.0001
log smoking 0.35 0.14 50.0001 0.14 0.05 0.014 0.41 0.18 50.0001
BMI n.t. 0.11 0.06 0.051 n.t.
Systolic blood pressure 0.13 0.16 0.024 N.S. N.S.
log blood glucose 0.18 0.19 0.002 N.S. 0.24 0.23 50.0001
Cholesterol 0.23 0.23 0.0001 0.14 0.08 0.015 0.23 0.27 50.0001
Fibrinogen N.S. 0.18 0.11 0.002 N.S.
All subjects (n 288) participated in the three regressions. Only variables associated with CPIMTmax with p values 50.30 in univariate
analysis were tested. N.S.not significant. n.t.not tested. Seq. R2 sequential R2. For all regressions the logarithm of CPIMTmax was
used as a dependent variable.







r coeff. p value r coeff. p value r coeff. p value
Age 0.05 0.512 0.20 0.046 ÿ0.00 0.948
log smoking 0.05 0.465 0.09 0.369 ÿ0.02 0.792
log alcohol 0.02 0.742 ÿ0.10 0.319 0.09 0.239
BMI 0.16 0.024 0.16 0.093 0.10 0.184
Systolic blood pressure 0.01 0.932 ÿ0.07 0.473 0.04 0.592
Diastolic blood pressure 0.01 0.867 ÿ0.06 0.522 0.08 0.324
log insulin 0.08 0.306 0.12 0.219 0.06 0.425
log blood glucose ÿ0.05 0.503 ÿ0.06 0.523 0.00 0.982
Cholesterol ÿ0.13 0.084 ÿ0.21 0.036 ÿ0.10 0.214
HDL cholesterol 0.02 0.756 ÿ0.00 0.980 0.01 0.929
log triglycerides ÿ0.09 0.227 ÿ0.18 0.064 ÿ0.06 0.430
Fibrinogen 0.10 0.159 0.01 0.910 0.08 0.278
log CRP 0.18 0.013 ÿ0.01 0.929 0.16 0.046
C3 complement 0.01 0.892 ÿ0.02 0.799 0.04 0.646
No. MPD p value No. MPD p value No. MPD p value
FHMI
No 159 33.0 (16.0±50.0) 0.587 89 31.5 (16.0±57.0) 0.419 140 31.0 (14.0±46.7) 0.871
Yes 24 25.7 (19.1±56.5) 15 29.0 (24.0±67.0) 23 22.0 (16.5±43.0)
Physical activity
No 113 26.7 (16.0±43.0) 0.086 64 28.0 (15.5±57.2) 0.079 102 26.7 (15.0±43.0) 0.569
Yes 70 38.3 (22.0±57.0) 40 39.0 (22.5±62.2) 61 33.0 (14.0±52.0)
Values for MPD are median (interquartile range). FHMI family history of myocardial infarction. HDLhigh density lipoprotein. p values
of the variables included in the subsequent multivariate analysis (p5 0.30) are marked in bold. For linear regressions the logarithm of MPD
was used as a dependent variable.
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noted that this population sample was not selected for
having advanced or complicated atherosclerotic
lesions. In general, the factors associated with pla-
que/intima-media thickness were not the same as
those associated with plaque density. Moreover, there
were differences among the acute phase proteins as
far as their associations with plaque characteristics
were concerned.
The only acute phase protein to be independently
associated with CPIMTmax after adjustment for
traditional risk factors was fibrinogen. However, for
reasons unknown, this was only observed at the
carotid bifurcation.19,27,30 Hyperfibrinogenaemia may
be a consequence of intra-plaque inflammation. Alter-
natively, fibrinogen may play a role in plaque devel-
opment through the formation of mural thrombi, the
stimulation of smooth muscle cell proliferation,28 or
the intimal trapping of lipoproteins.29 No relationship
between fibrinogen and MPD was detected.
The relationship between CRP and CPIMTmax dis-
appeared after adjustment for traditional risk factors,
which is in keeping with the earlier work of
others.31±33 On the other hand, CRP does seem to be
associated with plaque density, especially at the fem-
oral level, which supports the previously described
link between CRP and peripheral arterial disease34
but not carotid lesions.35 Relevant to this association
may be the fact that fibroblasts are important sources
of interleukin-6, the main trigger for CRP production
in the liver.36
With regard to C3, present data, unlike those from
earlier studies,37 are based on objective ultrasound
parameters, and fail to show any dependence on the
thickness or density of femoral and carotid plaques.
Thus, as previously suggested,10,16 the relationship
between C3 and the risk of myocardial infarction is
probably due to the role played by this cytokine/acute
phase protein upstream in the atherosclerotic process,
with a possible participation in the appearance of
the metabolic syndrome and its related cluster of
risk factors.
Overall traditional risk factors remain the main
determinants of plaque/intima-media thickness.
Several earlier studies have reached similar conclu-
sions, although in general acute phase proteins were
not measured, and the investigations were limited to
the carotid arteries.17,19,38 The association between ele-
vated triglyceride levels and low density carotid pla-
ques has already been reported by Grùnholdt et al.21,39
Furthermore, fibrinogen was the variable most closely
associated with the thickness of carotid plaques, and
CRP was the only specific marker, albeit weak, of high
plaque density in femoral arteries. However, no acute
phase protein was independently associated with the
presence of low density, potentially `` vulnerable'', pla-
ques in the sites explored.
Acknowledgements
This work was supported by grants from the Italian Ministry of
University and Scientific and Technological Research (MURST)
and the Inter-university Association for Cardiovascular Research
(CIRC).
References
1 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A
meta-analysis and review of the literature. Ann Intern Med 1993;
118: 956±963.
2 Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Inflammation, aspirin, and the risk of cardio-
vascular disease in apparently healthy men. N Engl J Med 1997;
336: 973±979.
3 Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive
protein and other markers of inflammation in the prediction of
cardiovascular disease in women. N Engl J Med 2000; 342: 836±843.
4 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A,
Landou C, Blomback M, Wiman B. Plasminogen activator inhi-
bitor in plasma: risk factor for recurrent myocardial infarction.
Lancet 1987; ii: 3±9.
5 Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A,
Rovinetti C, Descovich GC, Puddu P. Association of serum
C3 levels with the risk of myocardial infarction. Am J Med 1995;
98: 357±364.
6 Mendall MA, Patel P, Ballam L, Strachan D,
Northfield TC. C reactive protein and its relation to cardiovas-
cular risk factors: a population based cross sectional study. BMJ
1996; 312: 1061±1065.








Partial r Seq. R2 p value Partial r Seq. R2 p value Partial r Seq. R2 p value
Age n.t. 0.24 0.04 0.026 n.t.
BMI 0.15 0.02 0.040 0.24 0.06 0.028 N.S.
log triglycerides ÿ0.18 0.04 0.017 ÿ0.26 0.12 0.014 n.t.
log CRP 0.25 0.08 0.0008 n.t. 0.16 0.02 0.046
Physical activity 0.19 0.11 0.009 0.23 0.15 0.034 n.t.
Only variables associated with MPD with p values 50.30 in univariate analysis were tested. N.S.not significant. n.t.not tested. Seq.
R2 sequential R2. For all regressions the logarithm of MPD was used as a dependent variable.
86 A. Muscari et al.
Eur J Vasc Endovasc Surg Vol 26, July 2003
7 Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive
protein and cardiovascular risk factors in apparently healthy
men. Am J Cardiol 1999; 84: 1018±1022.
8 Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G,
Ferrieres J, Arveiler D, Juhan-Vague I. Associations of fibrino-
gen, factor VII and PAI-1 with baseline findings among 10 500
male participants in a prospective study of myocardial infarc-
tion. The Prime Study. Thromb Haemost 1998; 80: 749±756.
9 Muscari A, Massarelli G, Bastagli L, Poggiopollini G,
Tomassetti V, Volta U, Puddu GM, Puddu P. Relationship
between serum C3 levels and traditional risk factors for myocar-
dial infarction. Acta Cardiologica 1998; 53: 345±354.
10 Muscari A, Massarelli G, Bastagli L, Poggiopollini G,
Tomassetti V, Drago G, Martignani C, Pacilli P, Boni P,
Puddu P. Relationship of serum C3 to fasting insulin, risk factors
and previous ischemic events in middle aged men. Eur Heart J
2000; 21: 1081±1090, doi:10.1053/euhj.1999.2013.
11 Hotamisligil GS, Arner P, Caro JF, Atkinson RL,
Spiegelman BM. Increased adipose tissue expression of tumor
necrosis factor-alpha in human obesity and insulin resistance.
J Clin Invest 1995; 95: 2409±2415.
12 Hotamisligil GS, Budavari A, Murray D, Spiegelman BM.
Reduced tyrosine kinase activity of the insulin receptor in
obesity-diabetes. Central role of tumor necrosis factor-alpha.
J Clin Invest 1994; 94: 1543±1549.
13 Reaven GM. Insulin resistance and compensatory hyperinsuli-
nemia: role in hypertension, dyslipidemia, and coronary heart
disease. Am Heart J 1991; 121: 1283±1288.
14 Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med
1999; 340: 115±126.
15 Libby P. Molecular bases of the acute coronary syndromes.
Circulation 1995; 91: 2844±2850.
16 Muscari A, Bastagli L, Poggiopollini G, Tomassetti V,
Massarelli G, Cappelletti O, Plate' L, Boni P, Puddu P.
Different associations of C-reactive protein, fibrinogen and C3-
complement with traditional risk factors in middle-aged men. Int
J Cardiol 2002; 83: 63±71.
17 Paivansalo M, Rantala A, Kauma H, Lilja M, Reunanen A,
Savolainen M, Kesaniemi A, Suramo I. Prevalence of carotid
atherosclerosis in middle-aged hypertensive and control sub-
jects. A cross-sectional systematic study with duplex ultrasound.
J Hypertens 1996; 14: 1433±1439.
18 Beletsky VY, Kelley RE, Fowler M, Phifer T. Ultrasound
densitometric analysis of carotid plaque composition. Pathoana-
tomic correlation. Stroke 1996; 27: 2173±2177.
19 Ebrahim S, Papacosta O, Whincup P, Wannamethee G,
Walker M, Nicolaides AN, Dhanjil S, Griffin M,
Belcaro G, Rumley A, Lowe GD. Carotid plaque, intima
media thickness, cardiovascular risk factors, and prevalent
cadiovascular disease in men and women. The British Regional
Heart Study. Stroke 1999; 30: 841±850.
20 El-Barghouty N, Geroulakos G, Nicolaides A,
Androulakis A, Bahal V. Computer-assisted carotid plaque
characterisation. Eur J Vasc Endovasc Surg 1995; 9: 389±393.
21 Grùnholdt ML, Nordestgaard BG, Wiebe BM, Wilhjelm JE,
Sillesen H. Echo-lucency of computerized ultrasound images of
carotid atherosclerotic plaques are associated with increased
levels of triglyceride-rich lipoproteins as well as increased
plaque lipid content. Circulation 1998; 97: 34±40.
22 Biasi GM, Mingazzini PM, Baronio L, Piglionica MR,
Ferrari SA, Elatrozy TS, Nicolaides AN. Carotid plaque
characterization using digital image processing and its potential
in future studies of carotid endarterectomy and angioplasty.
J Endovasc Surg 1998; 5: 240±246.
23 Grùnholdt ML, Nordestgaard BG, Schroeder TV,
Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques
predict future strokes. Circulation 2001; 104: 68±73.
24 British Standards Institution. Precision of Test Methods I:
Guide for the Determination and Reproducibility for a Standard
Test Method (BS 5497, part 1). London: BSI, 1979.
25 Bland JM, Altman DG. Statistical methods for assessing agree-
ment between two methods of clinical measurement. Lancet 1986;
i: 307±310.
26 Clauss A. Gerinnungphysiologische Schnellmethode zur
Bestimmung des Fibrinogens. Acta Haematol 1957; 17:
237±246.
27 Lee AJ, Mowbray PI, Lowe GD, Rumley A, Fowkes FG,
Allan PL. Blood viscosity and elevated carotid intima-media
thickness in men and women: the Edinburgh Artery Study. Cir-
culation 1998; 97: 1467±1473.
28 Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation
products on the growth of rabbit aortic smooth muscle cells in
culture. Atherosclerosis 1982; 44: 161±174.
29 Sadoshima S, Tanaka K. Fibrinogen and low density lipopro-
tein in the development of cerebral atherosclerosis. Atherosclero-
sis 1979; 34: 93±103.
30 Leng GC, Papacosta O, Whincup P, Wannamethee G,
Walker M, Ebrahim S, Nicolaides AN, Dhanjil S,
Griffin M, Belcaro G, Rumley A, Lowe GD. Femoral athero-
sclerosis in an older British population: prevalence and risk
factors. Atherosclerosis 2000; 152: 167±174.
31 FerrieÁres J, Bongard V, Elias A, Ripoll L, Ruidavets JB,
Drouet L. Relationships between carotid and femoral
atherosclerosis and circulating inflammatory markers in a
general population sample. Eur Heart J 2001; 22 (Abstr.
Suppl.): 457.
32 Hulthe J, Wikstrand J, Fagerberg B. Relationship between
C-reactive protein and intima-media thickness in the carotid
and femoral arteries and to antibodies against oxidized low-
density lipoprotein in healthy men: the Atherosclerosis and Insu-
lin Resistance (AIR) study. Clin Sci 2001; 100: 371±378.
33 Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y,
Sakaguchi M, Nagai Y, Iyama S, Yamanishi H,
Matsumoto M, Hori M. C-reactive protein is an independent
predictor of the rate of increase in early carotid atherosclerosis.
Circulation 2002; 104: 63±67.
34 Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Plasma concentration of C-reactive protein
and risk of developing peripheral vascular disease. Circulation
1998; 97: 425±428.
35 Grùnholdt MLM, Sillesen H, Wiebe BM, Laursen H,
Nordestgaard BG. Increased acute phase reactants are asso-
ciated with levels of lipoproteins and increased carotid plaque
volume. Eur J Vasc Endovasc Surg 2001; 21: 227±234, doi:10.1053/
ejvs.2001.1321.
36 Baumann H, Gauldie J. The acute phase response. Immunol
Today 1994; 15: 74±80.
37 Muscari A, Massarelli G, Bastagli L, Poggiopollini G,
Tomassetti V, Drago G, Martignani C, Pacilli P, Pati R,
Puddu P. Different relationship of C3, C-reactive protein and
fibrinogen with arterial plaque echostructure. JACC 1998; 31
(Suppl. C): 204 (abstract).
38 FerrieÁres J, Elias A, Ruidavets JB, Cantet C, Bongard V,
Fauvel J, Boccalon H. Carotid intima-media thickness and
coronary heart disease factors in a low-risk population. J Hyper-
tens 1999; 17: 743±748.
39 Grùnholdt MLM, Nordestgaard BG, Nielsen TG, Sillsen H.
Echolucent carotid artery plaques are associated with elevated
levels of fasting and postprandial triglyceride-rich lipoproteins.
Stroke 1996; 27: 2166±2172.
Accepted 13 January 2003
Acute Phase Proteins and Traditional Risk Factors 87
Eur J Vasc Endovasc Surg Vol 26, July 2003
